These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3826095)

  • 21. Frequency of Gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic.
    Cermák P; Kolár M; Látal T
    Int J Antimicrob Agents; 2004 Apr; 23(4):401-4. PubMed ID: 15081092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Bacteremias in a university hospital: study of etiologic agents and their sensitivity patterns].
    Betriu C; Palau L; Gómez M; Sánchez A; Romero J; Picazo JJ
    Rev Clin Esp; 1999 Aug; 199(8):503-10. PubMed ID: 10522430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility of bacterial isolates to cefepime in comparison to other broad spectrum antimicrobial agents at a tertiary care center in Lebanon.
    Kanj SS; Chedid M; Araj GF
    J Med Liban; 2001; 49(1):13-7. PubMed ID: 11910959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid identification and susceptibility testing using the VITEK 2 system using culture fluids from positive BacT/ALERT blood cultures.
    Chen JR; Lee SY; Yang BH; Lu JJ
    J Microbiol Immunol Infect; 2008 Jun; 41(3):259-64. PubMed ID: 18629422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility pattern of uropathogenic gram negative bacilli to antimicrobial chemotherapeutic agents in a National Hospital in Dar es Salaam.
    Urassa WK; Mwakagile D; Mohammed K; Msangi V
    East Afr Med J; 1997 Mar; 74(3):162-5. PubMed ID: 9185413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro activity of piperacillin and tazobactam combination against clinically significant bacteria.
    Obi CL; Makandiramba B; Robertson V; Tswana SA; Moyo SR; Nziramasanga P
    East Afr Med J; 1998 Mar; 75(3):162-5. PubMed ID: 9640815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ['In vitro' activity of different antimicrobial agents on Gram-negative nonfermentative bacilli, excluding Pseudomonas aeruginosa and Acinetobacter spp].
    Vay CA; Almuzara MN; Rodríguez CH; Pugliese ML; Lorenzo Barba F; Mattera JC; Famiglietti AM
    Rev Argent Microbiol; 2005; 37(1):34-45. PubMed ID: 15991478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How does susceptibility prevalence impact on the performance of disk diffusion susceptibility testing?
    Lamy B; Carret G; Flandrois JP; Delignette-Muller ML
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):131-9. PubMed ID: 15183863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization and anti-microbial susceptibility of gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan.
    Saghir S; Faiz M; Saleem M; Younus A; Aziz H
    Indian J Med Microbiol; 2009; 27(4):341-7. PubMed ID: 19736404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007.
    Guembe M; Cercenado E; Alcalá L; Marín M; Insa R; Bouza E
    Rev Esp Quimioter; 2008 Sep; 21(3):166-73. PubMed ID: 18792817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical limitations of in vitro testing of microorganism susceptibility.
    Nightingale J
    Am J Hosp Pharm; 1987 Jan; 44(1):131-7. PubMed ID: 3826085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antimicrobial susceptibility testing in clinically relevant non-fermenting gram-negative bacilli: recommendations from the Antimicrobial Agents Subcommittee of the Sociedad Argentina de Bacteriología, Micología y Parasitología Clínicas, Asociación Argentina de Microbiología].
    Radice M; Marín M; Giovanakis M; Vay C; Almuzara M; Limansky A; Casellas JM; Famiglietti A; Quinteros M; Bantar C; Galas M; Kovensky Pupko J; Nicola F; Pasterán F; Soloaga R; Gutkind G
    Rev Argent Microbiol; 2011; 43(2):136-53. PubMed ID: 21731977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bacterial susceptibility to chemotherapeutic agents (Zurich, 1987)].
    Wüst J; Kayser FH
    Schweiz Rundsch Med Prax; 1989 Jun; 78(26):745-50. PubMed ID: 2756266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The wet disc antimicrobial solution assay. An in vitro method to test efficacy of antimicrobial solutions for topical use.
    Holder IA
    J Burn Care Rehabil; 1989; 10(3):203-8. PubMed ID: 2745497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro testing of antimicrobial agents.
    Washington JA
    Infect Dis Clin North Am; 1989 Sep; 3(3):375-87. PubMed ID: 2671127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial formulary management: meeting the challenge in the community hospital.
    Rush DR
    Pharmacotherapy; 1991; 11(1 ( Pt 2)):19S-26S. PubMed ID: 2011569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experience with selective reporting of susceptibility to antimicrobial agents.
    Brodowy BA; Guglielmo BJ; York MK; Herfindal ET; Brooks GF
    Am J Hosp Pharm; 1989 Sep; 46(9):1816-8. PubMed ID: 2801717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial susceptibility testing in India - a status survey.
    Sudha V; Prasad A; Khare S; Bhatia R
    Indian J Med Microbiol; 2001; 19(4):222-3. PubMed ID: 17664840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA probes for antimicrobial susceptibility testing.
    Tenover FC
    Clin Lab Med; 1989 Jun; 9(2):341-7. PubMed ID: 2659247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.